Breast cancer cells can switch between estrogen receptor α and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance
- DOI
- 10.1007/s10549-009-0506-y
- Published
- 2009-08-21
- Container
- Breast Cancer Research and Treatment
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s10549-009-0506-y,
title = {Breast cancer cells can switch between estrogen receptor α and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance},
author = {Katrine Sonne-Hansen and Ida C. Norrie and Kristina B. Emdal and Rikke V. Benjaminsen and Thomas Frogne and Ib J. Christiansen and Tove Kirkegaard and Anne E. Lykkesfeldt},
year = {2009},
journal = {Breast Cancer Research and Treatment},
doi = {10.1007/s10549-009-0506-y},
url = {https://doi.org/10.1007/s10549-009-0506-y}
}RIS
TY - JOUR TI - Breast cancer cells can switch between estrogen receptor α and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance AU - Katrine Sonne-Hansen AU - Ida C. Norrie AU - Kristina B. Emdal AU - Rikke V. Benjaminsen AU - Thomas Frogne AU - Ib J. Christiansen AU - Tove Kirkegaard AU - Anne E. Lykkesfeldt PY - 2009 JO - Breast Cancer Research and Treatment DO - 10.1007/s10549-009-0506-y UR - https://doi.org/10.1007/s10549-009-0506-y ER -
APA
Sonne-Hansen, K., Norrie, I. C., Emdal, K. B., Benjaminsen, R. V., Frogne, T., Christiansen, I. J., Kirkegaard, T., & Lykkesfeldt, A. E. (2009). Breast cancer cells can switch between estrogen receptor α and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-009-0506-y
Source records
- crossref · retrieved 2026-11-07T09:46:56.724Z